Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1920 ARTÍCULOS , VIENDO DEL 586 AL 600

Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?

Liu N, Haziyihan A, Zhao W, Chen Y, Chao H.

Transl Neurodegener. 2024 Aug 19;13(1):42. doi: 10.1186/s40035-024-00434-9.

Autoimmune hypothesis of Alzheimer's disease: unanswered question

Arshavsky YI.

J Neurophysiol. 2024 Sep 1;132(3):929-942. doi: 10.1152/jn.00259.2024. Epub 2024 Aug 20.

Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease

Hegedűs É, Pákáski M, Gosztolya G, Hoffmann I, Kovács I, Kálmán J.

PLoS One. 2024 Aug 20;19(8):e0308409. doi: 10.1371/journal.pone.0308409. eCollection 2024.

Targeting STAT3 signaling pathway in the treatment of Alzheimer's disease with compounds from natural products

Wen X, Hu J.

Int Immunopharmacol. 2024 Nov 15;141:112936. doi: 10.1016/j.intimp.2024.112936. Epub 2024 Aug 19.

Menopause and Alzheimer's disease susceptibility: Exploring the potential mechanisms

Breeze B, Connell E, Wileman T, Muller M, Vauzour D, Pontifex MG.

Brain Res. 2024 Dec 1;1844:149170. doi: 10.1016/j.brainres.2024.149170. Epub 2024 Aug 18.

Brain resident microglia in Alzheimer's disease: foe or friends

Kaur S, K M, Sharma A, Giridharan VV, Dandekar MP.

Inflammopharmacology. 2024 Oct;32(5):2781-2800. doi: 10.1007/s10787-024-01550-8. Epub 2024 Aug 21.

Coffee and Alzheimer's disease

Mirzaei F, Agbaria L, Bhatnagar K, Sirimanne N, Omar A'amar N, Jindal V, Gerald Thilagendra A, Tawfiq Raba F.

Prog Brain Res. 2024;289:21-55. doi: 10.1016/bs.pbr.2024.06.002. Epub 2024 Jul 3.

Recent Molecular Targets and their Ligands for the Treatment of Alzheimer Disease

Bayraktar G, Alptüzün V.

Curr Top Med Chem. 2024;24(28):2447-2464. doi: 10.2174/0115680266318722240809050235.

ADAM10 isoforms: Optimizing usage of antibodies based on protein regulation, structural features, biological activity and clinical relevance to Alzheimer's disease

Dorta S, Alexandre-Silva V, Popolin CP, de Sousa DB, Grigoli MM, Pelegrini LNC, Manzine PR, Camins A, Marcello E, Endres K, Cominetti MR.

Ageing Res Rev. 2024 Nov;101:102464. doi: 10.1016/j.arr.2024.102464. Epub 2024 Aug 21.

Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges

Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS.

Life Sci. 2024 Oct 15;355:123001. doi: 10.1016/j.lfs.2024.123001. Epub 2024 Aug 21.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L.

Signal Transduct Target Ther. 2024 Aug 23;9(1):211. doi: 10.1038/s41392-024-01911-3.

Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease

Zhang Y, Yu W, Zhang L, Li P.

Expert Opin Investig Drugs. 2024 Oct;33(10):1047-1062. doi: 10.1080/13543784.2024.2396911. Epub 2024 Aug 26.

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)

Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS.

J Alzheimers Dis. 2024;101(1):353-367. doi: 10.3233/JAD-240221.

Fueling Alzheimer's Disease: Where Does Immunometabolism Stand?

Correia SC, Perry G, Moreira PI.

J Alzheimers Dis. 2024;100(s1):S363-S385. doi: 10.3233/JAD-240787.

Harmony of Wnt pathway in Alzheimer's: Navigating the multidimensional progression from preclinical to clinical stages

Varshini MS, Reddy RA, Krishnamurthy PT, Wadhwani A.

Neurosci Biobehav Rev. 2024 Oct;165:105863. doi: 10.1016/j.neubiorev.2024.105863. Epub 2024 Aug 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias